On May 14, 2024 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, reported the acceptance of a poster presentation at the upcoming European Hematology Association (EHA) (Free EHA Whitepaper) Hybrid Congress being held in Madrid, Spain from June 13-16, 2024 (Press release, Adicet Bio, MAY 14, 2024, View Source [SID1234643278]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation are as follows:

Title: ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T Cell Therapy Designed for Multiple Solid and Hematological Cancer Indications
Presenting Author: Yvan Chanthery, Ph.D.
Date & Time: June 14, 2024 at 18:00 CEST